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E-mail address: ailomonte@unipa.it (A.I. Lo MonteSecondary hyperparathyroidism (HP) presenting with hypocalcemia and subsequent increased parathor-
mone (PTH), is mainly identiﬁed in patients with chronic renal failure, which has been associated with
variable degrees of bone marrow ﬁbrosis.
For suitable patients with end-stage renal disease (ESRD), kidney transplantation is recognized as the
therapy of choice, being superior to dialysis in terms of quality of life and long-term mortality risk; in this
regard interesting data show that increased time on dialysis prior to kidney transplantation is associated
with decreased graft and patient survival.
In our opinion an important and until now underestimated determinant of graft survival is the proper
activity of bone marrow because of the emerging role of hematopoietic stem cells (HSC) in repair of ische-
mia/reperfusion (IR) damage. We postulate that in ESRD patients, who usually undergo long dialytic
treatment, a myeloﬁbrosis caused by an overt secondary HP could drastically decrease the HSC potential
for IR damage repair after kidney transplant; this could irremediably lead to a delay in graft function with
all related complicances.
If the curative role of bone marrow-derived stem cells was conﬁrmed by more data obtained in exper-
imental animal models, it could be possible to try a cellular-based therapeutic approach in the manage-
ment of ESRD patients which are in waiting list for a kidney transplant.
 2011 Elsevier Ltd. All rights reserved.Introduction
Bone marrow ﬁbrosis occurs in pathological states that
characterize idiopathic myeloﬁbrosis [1,2] and hyperparathyroid
bone disease [3]. While recent investigations have identiﬁed
important constituents within ﬁbrotic marrow in patients who
have certain hematologic malignancies, little is known about the
pathogenesis of marrow ﬁbrosis that occurs in patients with renal
osteodystrophy.
Speciﬁcally, questions regarding ﬁbrosis composition, its gene-
sis and the potential role of parathyroid hormone (PTH) in the
ﬁbrous replacement of the marrow space remain to be answered.
As seen from studies of idiopathic myeloﬁbrosis, growth factors
and cytokines are believed to promote a marrow proliferative
response and the accumulation of extracellular matrix proteins
[2]. Whether these factors are also implicated in uremic bone dis-ll rights reserved.
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).ease is unknown. However, cytokines and locally derived growth
factors have important roles in regulating normal bone metabolism
and circulating levels of speciﬁc cytokines are elevated in renal
failure [4,5].
Cytokines are particularly important in modulating the bone
resorptive phase of the remodeling cycle [6], thus the ﬁnding that
PTH can stimulate selective cytokine synthesis [7] suggests that
hyperparathyroidism may be a signiﬁcant stimulus for cytokine
accumulation in renal osteodystrophy.
There has been much interest in the reparative and angiogenic
properties of stem cells from bone marrow [8–10] and several
studies in mouse models of kidney disease have shown that mouse
mesenchymal stromal cells of bone marrow can prevent or atten-
uate kidney injury, possibly by paracrine or systemic secretory
mechanisms. However, the possible angiogenic role of hematopoi-
etic stem/progenitor cells (HSPCs) in kidney repair has been little
explored, and no studies have ascertained the practicability of har-
vesting human HSPCs in cell therapy to promote organ repair and
regeneration [11].
The kidney peritubular microvasculature has received increas-
ing attention recently because this fragile vasculature may not
regenerate normally after injury. This may predispose to chronic
558 M. Bellavia et al. /Medical Hypotheses 77 (2011) 557–559ischemia of the kidney [12,13] triggering chronic inﬂammation,
tubular atrophy, and interstitial ﬁbrosis, hallmarks of chronic kid-
ney disease.Hypothesis
Ischemia and reperfusion (I/R) injury is the ﬁrst insult to a
transplanted organ. In renal grafts I/R injury is followed by delayed
graft function (DGF), which is the most common complication in
the immediate period, when the transplant is performed from a de-
ceased donor. The immediate consequences of I/R injury are pro-
longed hospitalization, increased costs, and greater complexity of
immunosuppressive drug management. Some trials have demon-
strated association between DGF and risk of acute rejection epi-
sodes (ARE); therefore, I/R injury may be related to a reduced
graft survival [14,15].
We believe that one of the main causes of DRG could be a mye-
loﬁbrosis secondary to an overt secondary hyperparathyroidism
arisen in long-term dyalisis patients who are in waiting list for a
kidney transplant. Bone marrow ﬁbrosis could infact lead to a de-
creased level of HSC and ﬁnally to a drastic compromission of the
repair of IR damage [16].Evaluation of hypothesis and discussion
Recent studies have shown that CD34+ hematopoietic cells,
originating from the bone marrow, can differentiate into an endo-
thelial phenotype and form a subpopulation of circulating cells
called endothelial progenitor cells (EPCs) [17].
It has been shown that in uremic patients high serum level of
parathyroid hormone (PTH) was associated with a decrease in cir-
culating CD34+ cells [18]; authors suggest a role of uremic toxins
in such an inverse relation. We think that another explanation
could involve bone marrow ﬁbrosis which is sometimes found in
association with hyperparathyroidism; from this point of view
the low level of circulating CD34+ cells could not only be caused
by toxic activity of uric acid and related compounds [19,20] but
also it could correlate with a decreased production of these cells
in a ﬁbrotic bone marrow.
In favor of this argument published data by Jourde-Chiche et al.
[21] showed that in hemodyalisis (HD) patients CD34+ CD133+
immature progenitor cells number was negatively correlated with
the levels of uremic toxins b2-microglobulin and indole-3acetic
acid, but myeloid endothelial progenitor cells number positively
correlated with markers of vascular injury assessed by measuring
aortic pulse wave velocity and plasma level of endothelial
microparticles.
This evidence could be explained postulating that uremic toxins
exerted a deleterious effect on progenitor cells early in the
differentiation process, but also that vascular injury stimulated a
mobilization of EPC from bone marrow. Interestingly all HD
patients have not a very signiﬁcant alteration of calcium/phospho-
rus metabolism; consequently none of them suffer from an overt
secondary hyperparathyroidism which could have caused a
myeloﬁbrosis.
It has been also reported that in patients on long-term hemod-
ialysis the total number of EPC increased but the cells were charac-
terized by pronounced functional impairment particularly in term
of reduced migratory activity and ability to adhere to matrix
proteins [22]; in this case it should be emphasized that all patients
have a high serum level of PTH (about 250 pg/mL) which is an
hallmark of HP. It could be possible to postulate that also in this
case a not properly diagnosed myeloﬁbrosis, secondary to HP,
could have compromised the ability of bone marrow to produce
functional EPC.Consequences of hypothesis
Bone marrow-derived stem cells appear to have a capacity for
trans differentiation and to repair damaged renal tissue by replac-
ing tubular epithelial cells [23], mesangial cells [24,25], endothelial
cells [26] and even podocytes [27,28]. Although bone marrow con-
tains several cell types including hematopoietic stem cells (HSC),
mesenchymal stromal cells (MSC) and endothelial progenitor cells
(EPC), engraftment of bone marrow-derived cells to kidney is most
likely to have been due to the MSC population [29,30].
Patients suffering from renal failure and related secondary
hyperparathyroidism, subjected to a dialysis treatment and in
waiting list for a kidney transplant, could have a decreased number
of different types of bone marrow derived progenitor cells (BMDC)
because of the onset of a myeloﬁbrosis [31]. In this cases, if the
regenerative role of BMDC was conﬁrmed in experimental animal
models, it could be possible to plan a blood collection of these cells
before the onset of myeloﬁbrosis with the aim to infuse them
in situ again after kidney transplant helping the functional recovery
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